Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report.

Publication

Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report.

Journal Paper/Review - Dec 12, 2017

Weber Nina T, Sigaroudi Ali, Ritter Alexander, Boss Andreas, Lehmann Kuno, Goodman David, Farese Stefan, Weiler Stefan, Müller Thomas F

Citation

Weber N, Sigaroudi A, Ritter A, Boss A, Lehmann K, Goodman D, Farese S, Weiler S, Müller T. Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report. BMC Nephrol 2017; 18:360.

Type

Journal Paper/Review (English)

Journal

BMC Nephrol 2017; 18

Publication Date

Dec 12, 2017

Issn Electronic

1471-2369

Pages

360

Brief description/objective

Mycophenolic acid (MPA), either given as an ester pro-drug or as an enteric-coated sodium salt, is the most commonly prescribed anti-proliferative immunosuppressive agent used following organ transplantation and widely applied in immune-mediated diseases. Clinicians are well aware of common adverse reactions related to MPA treatment, in particular diarrhea, leukopenia and infections. Here we report a case of severe, persistent ascites associated with MPA treatment. The otherwise unexplained and intractable ascites, requiring repeated paracenteses for more than 8 months, rapidly ceased with stopping the MPA treatment. To our knowledge this is the first case of severe ascites associated with MPA treatment reported in the scientific literature.